Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY21479 Risk Adapted De-Intensification of Radio Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate. To determine if Risk-Adapted De-Intensification of RT and chemotherapy based on HPV subtype, cfHPV DNA level, and cfHPV DNA clearance rate produces LRC rates that are similar to what has been achieved with more aggressive therapy in patients with for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma. To assess the 2-year clinical outcomes of local control (LC), regional control (LRC), disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS) in all treated patients. To evaluate the potential value of cfHPV DNA level after treatment to detect residual or recurrent cancer. To evaluate head and neck quality of life assessments before, during, and after RT in all treated patients. To evaluate speech and swallowing function after RT in all treated patients. Study Information
STUDY21565 A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.) To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s) To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS], and duration of response [DOR]) of E7386 in combination with other anticancer drug(s) (Revised per Amendment 06) Study Information
STUDY22304 A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado Trastuzumab Emtansine For Recurrent, Metastatic or Treatment Naïve, Unresectable HER-2 Positive Salivary Gland Cancer To determine if trastuzumab emtansine (ado-trastuzumab emtansine [T-DM1]) shows better progression-free survival (PFS) when compared to docetaxel plus trastuzumab (TH) in recurrent and/or metastatic (R/M) HER2-positive salivary gland cancer (SGC) patients who have not previously received HER2 therapy for unresectable or recurrent and/or metastatic disease, as determined by local assessment. Study Information
STUDY23278 Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). To evaluate additional endpoints of efficacy for ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with R/M HNSCC. Study Information